in vivo News and Research

RSS

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

Experts at Virgen del Rocío Hospital (Seville, Spain) have begun a study on pregnancy preeclampsia on a sample of 30 pregnant women with a view to demonstrating whether or not consumption of olive oil by this population group results in lower levels of cytotoxicity (for example, cholesterol) in endothelial cells (arterial wall cells).

19 Nov 2009

New study sheds light on potassium pore dynamics and serves as an important foundation for research

The December 2009 issue of the Journal of General Physiology (JGP) contains a paper by Christopher Ahern (The University of British Columbia, Vancouver) and colleagues that explores pore mutation effects in Shaker and other K+ channels using in vivo nonsense suppression technology. The study will be published online November 16 (www.jgp.org).

19 Nov 2009

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.

18 Nov 2009

Pre-clinical data of GM1485 to be presented by GliaMed

GliaMed, Inc., a development stage biopharmaceutical company, today announced that Dr. David Weinstein, chief scientific officer and company founder, will present pre-clinical data demonstrating acceleration of wound healing through the in vivo induction and recruitment of stem cells at the Stem Cells USA & Regenerative Medicine Congress in Washington, D.C.

18 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Flamel Technologies today announced its financial results for the third quarter of 2009.

16 Nov 2009

Columbia University Medical Center presents the 2009 Naomi Berrie Awards

Columbia University Medical Center will present the 2009 Naomi Berrie Awards to a nationally recognized diabetes researcher, and a promising young investigator, for their outstanding achievements in diabetes research.

16 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Geron Corporation today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

UK research funders announce support for a series of H1N1 2009 research projects

Leading UK research funders today announce -7.5 million of funding for a series of projects aimed at understanding the development and spread of pandemic influenza H1N1 2009 - or 'swine flu'. The research will look at every aspect of the virus, on pig farms, in pig and human populations, and in hospital intensive care units.

11 Nov 2009

Glissandra Skincare launches three signature anti-aging products

Glissandra™ Skincare Inc. announced the global launch of its three signature anti-aging products concurrent with the Israel Cancer Research Fund’s “Women of Action” awards luncheon honoring Beverly Cohen, Lisi Harrison, and Vivien Zighelboim, Ph.D, at the Four Seasons Hotel, Los Angeles at Beverly Hills.

11 Nov 2009

VeriChip announces the completion of Steel Vault acquisition

VeriChip Corporation, a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs, and Steel Vault Corporation, a premier provider of identity security products and services, announced today that VeriChip has completed its acquisition of Steel Vault to provide unique health and security identification tools to protect consumers and businesses. In conjunction with the merger, VeriChip has changed its name to PositiveID ("PositiveID" or the "Company").

11 Nov 2009

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

The National Institutes of Health (NIH) has awarded researchers at Rice University and the Texas Heart® Institute (THI) a $1 million Challenge Grant to refine cell-tracking nanotube technology that could make magnetic resonance imaging (MRI) up to 40 times more sensitive than existing MRIs and help guide adult stem cells within the human body to repair damaged hearts.

10 Nov 2009

Activating TAp63 protein, a viable anti-cancer strategy

Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

10 Nov 2009

in vivo News and Research

VisEn Medical launches two new agents for imaging quantification

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

New study sheds light on potassium pore dynamics and serves as an important foundation for research

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Pre-clinical data of GM1485 to be presented by GliaMed

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Columbia University Medical Center presents the 2009 Naomi Berrie Awards

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

New Cat B 750 FAST imaging agent launched by VisEn Medical

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Stapled Peptides directly inhibit the Notch transcription factor complex

Transplantation of hESC-derived OPCs spare spinal cord tissue in the cervical lesion site: Study

Stapled Peptides can inhibit key intracellular biological targets, says new research

UK research funders announce support for a series of H1N1 2009 research projects

Glissandra Skincare launches three signature anti-aging products

VeriChip announces the completion of Steel Vault acquisition

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

Activating TAp63 protein, a viable anti-cancer strategy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News